skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

What is Citeline?

Clinical R and D

Citeline is the industry’s most comprehensive, reliable and current global R&D intelligence suite of solutions. Built by experts, made for experts, Citeline solutions transform data into knowledge. And now our new, next generation platform delivers unparalleled access to Citeline’s robust clinical trial intelligence. With greater ease, speed and efficiency than ever before, Citeline’s next generation platform will help you gain critical insights into the global clinical trial landscape and realize greater cost-savings as you develop on your clinical trial programs.

What Citeline does: 

Citeline organizes vast quantities of data with human intelligence to greatly reduce research time, clinical trial costs and optimize trial outcomes. It features an unmatched collection of critical information on global clinical trials, investigators and sites, and drug development pipelines all with direct expert analyst support. Stay updated on what your competitors are doing with full public domain coverage of over 40,000 sources, continuous updating and full record reviews, advanced indexing and proprietary content.

Gain key insights that can be turned into actionable results with unparalleled access to 265,000+ clinical trials, 400,000 investigators, 68,000+ drugs, 117,000+ sites, 235+ diseases in 8 major therapeutic areas across 166 countries. And our 250+ therapeutic area experts and analysts are dedicated to provide the support needed so that you’re getting the most appropriate data to meet your requirements.

Citeline solutions:

 

If you are a Citeline subscriber, please access your login here.

Related products

sitetrove-pharmaintelligence

Sitetrove: 治験責任医師と治験施設情報のデータベース

Sitetrove(サイトトローブ)は、170か国・40万人以上の治験責任医師(PI: Principal Investigator)と235以上の疾患に対応する11万7千か所以上の治験施設に関する情報を収録するデータベースです。治験責任医師と治験施設に関して業界で最も正確で包括的な情報を提供することで、コスト増につながる治験の遅延を最小化し、お客様の臨床試験を成功に導くようサポートします。Sitetroveに登録される治験責任医師は、豊富な臨床経験や治験に関する十分な知識をもっていることをアナリストにより精査されています。

Key benefits:

  • 治験責任医師と治験施設情報のデータベース
  • 疫学ダッシュボードは見やすいマップビュー
  • Ask-the-Analyst機能で情報に基づく意思決定
trial-trove-pharma intelligence

Trialtrove: 医療用医薬品の臨床試験情報データベース

Trialtrove(トライアルトローブ)は医療用医薬品の開発状況を常に把握できる医薬品業界随一の臨床試験情報データベースです。計画段階から完了まで、260疾患・29万件の臨床試験をトラッキングし、250以上の学会をカバーしています。4万以上の情報ソースから収録した臨床試験に関するデータを250名のアナリストが精査し、リアルタイムで更新しています。学会発表や企業発のニュースは即日収録されます。アラート機能や可視化ツールを活用することで、特定の臨床試験のモニタリングや資料作成も可能です。

Key benefits:

  • 専門家による情報精査
  • 世界中の臨床試験情報を網羅
  • 標準治療に関する情報
pharma intelligence pharma banner

Pharmaprojects: 医薬品開発パイプラインのデータベース

Pharmaprojects(ファーマプロジェクツ)は、医薬品業界で代表的な開発パイプライン(医療用医薬品候補化合物)のデータベースとして、医薬品企業をはじめとする多くのお客様にご利用いただいています。前臨床試験から上市済み医薬品まで、現在開発中の15,000の薬剤を含む68,000以上の開発パイプライン情報を収録しています。さらに、43,000以上の医薬品を網羅した35年間にわたる過去のデータベースにもアクセスできます。グローバル競争が激しくなる中、競合分析や研究開発戦略の策定に威力を発揮するデータベースです。

Key benefits:

  • 医療用医薬品の研究・開発パイプライン情報
  • 35年間にわたる過去のヒストリカルデータも
  • Ask-the-Analyst機能で情報に基づく意思決定
Citeline analytics

Citeline Analytics

Citeline’s Custom Analytics service provides expert analytical and project-orientated support for your strategic business questions.

Key benefits:

  • Actionable intelligence
  • Expert Analysis
  • Tailored solutions

無料の最新記事&レポート

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Six of the Greatest Therapeutic R&D Challenges

    23 Aug 2019

    Explore the six biggest therapeutic R&D challenges facing the industry today with a free infographic from In Vivo.  This snapshot view of the major issues facing R&D is packed with data and insights about everything from drug resistance to diagnostics challenges.  

    Topic drug-development-landscape

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    In Vivo Content - Relied Upon by Senior Decision Makers

    21 Aug 2019

    There are many ways to market your brand and establish your business as a thought leader - but none of these methods compare to the distinct advantage gained through marketing with In Vivo and Informa Pharma Intelligence. The articles, news and interviews we feature are used daily by senior decision-makers to support their decisions, and to keep abreast of what their competitors are doing. 

    Topic business-strategies medtech

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    MedTech Forum 2019: The Future Is Here But Industry Still Needs A Long-Term Vision

    By Ashley Yeo 16 Aug 2019

    In a world where national economies are beset by conflicting spending priorities, health care is oftentimes too low on the agenda, health care observers say. One of these is Boston Scientific senior vice-president Eric Thépaut, who understands the dilemmas, but says that health care will soon force its way up the priority list. He has advice for future-ready medtech innovators.

    Topic Medtech Business strategies

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Could The Gut Cure Brain Disease?

    By Melanie Senior 08 Aug 2019

    Scientists now understand that there are multiple, bi-directional links between gut and brain. They are using this knowledge to develop new treatments for some of the most challenging chronic conditions, including Alzheimer’s disease, Parkinson’s disease and obesity.

    Topic diseases

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Meet the 2019 Titans of Pharma

    31 Jul 2019

    Get exclusive info on the leaders of the Pharma industry.The 2019 Titan of Pharma infographic is a snapshot of the industry’s top leaders and the businesses they oversee.

    Topic company-analysis strategy

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

    By William Looney 30 Jul 2019

    In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets. 

    Topic brexit policy-and-regulation

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, In Vivo: 医療用医薬品・医療機器産業の経営層向けニ...

    AI in the Pharmaceutical Landscape

    25 Jul 2019

    AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.

    Topic digital-health strategy medtech

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    MedTech Forum 2019: In The Medtech Glasshouse, Industry Need Not Fear Stones

    12 Jul 2019

    Medtech’s contribution to health care improvements in Europe over the past 30 years has been a phenomenal journey of success – in patient terms as well as in commercial terms, says MedTech Europe chair Rob ten Hoedt. Local creativity has been able to mine a seam of product innovation that is unmatched anywhere in the world, but the sector is facing massive change and must find ways to cope.

    Topic Medtech Digital Health

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    New Science As A Business Growth Strategy

    By Sanskriti Thakur and Gordon Murphy 04 Jul 2019

    Finding innovative ways to adapt the biopharma business model to external and internal challenges is a key competitive differentiator for today’s C-suite leadership.

    Topic BioPharmaceutical Research

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom

    02 Jul 2019

    No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.

    Topic clinical-trials

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

    02 Jul 2019

    Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

    Topic BioPharmaceutical

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    David Or Goliath: Where Is Innovation Winning Through?

    By Lucie Ellis 02 Jul 2019

    With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies.

    Topic BioPharmaceutical Drug approval Drug development landscape Drug review

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

    By William Looney 02 Jul 2019

    The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.

    Topic clinical-trials

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, Pink Sheet: 世界の薬事規制と承認審査に関するニ...

    医療用医薬品、医療機器、薬事規制ニュース

    21 Jun 2019

    インフォーマ・ファーマインテリジェンスでは、医薬品とバイオテック及び医療機器を含む世界のヘルスケア産業全般に関するニュースを配信しています。65名のジャーナリストと300名超のアナリストが、独立した立場と分析でグローバル化した今日の医薬品産業のニュースをお伝えします。

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Cancer Vaccines: Is There A Future Beyond Trial And Error?

    By William Looney 11 Jun 2019

    Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.

    Topic Cancer Vaccines

医薬品産業専門のジャーナリスト&アナリスト

Management

Susan Danheiser

Management, Director

Boston

Susan Danheiser

Susan specializes in

  • Commercial Strategy
  • Clinical Trials
  • Oncology
  • Neurology

+22 year(s) experience

製品説明を兼ねた無料デモ&お問い合わせ

専任スタッフによる詳しい説明を兼ねた無料デモンストレーションを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。